Size of Extranodal Extension on Sentinel Lymph Node Dissection in the American College of Surgeons Oncology Group Z0011 Trial Era | Zendy

Audrey H. Choi | Zendy; Summer Blount | Zendy; Mia Perez | Zendy; Carlos E. Chavez de Paz | Zendy; Samuel Rodriguez | Zendy; Matthew Surrusco | Zendy; Carlos A. Garberoglio | Zendy; Sharon S. Lum | Zendy; Maheswari Senthil | Zendy

Open Access

Size of Extranodal Extension on Sentinel Lymph Node Dissection in the American College of Surgeons Oncology Group Z0011 Trial Era

Author(s) -

Audrey H. Choi,

Summer Blount,

Mia Perez,

Carlos E. Chavez de Paz,

Samuel Rodriguez,

Matthew Surrusco,

Carlos A. Garberoglio,

Sharon S. Lum,

Maheswari Senthil

Publication year - 2015

Publication title -

jama surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.757

H-Index - 176

eISSN - 2168-6262

pISSN - 2168-6254

DOI - 10.1001/jamasurg.2015.1687

Subject(s) - medicine , breast cancer , sentinel lymph node , axillary lymph node dissection , lymph node , lymph , surgery , dissection (medical) , cohort , retrospective cohort study , cancer , pathology

Based on the American College of Surgeons Oncology Group Z0011 trial exclusion criteria, patients with T1N0 or T2N0 breast cancer with 1 or 2 positive sentinel lymph nodes (SLNs) are recommended to undergo axillary lymph node dissection if extranodal extension (ENE) is present.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research